You are here

Global Cancer Technology

Summary

Invest in Remote-Controlled Drug Delivery

Listen to a message from the founder of Global Cancer Technology (GCT), John Clark

John Clark is a seasoned and serial entrepreneur with deep expertise in medical technologies. In this video, he offers insights into some of the technology available to GCT and how their innovative approach to deliver cancer and other treatments can be remote-controlled for exceptional precision and timing.

Cancer Treatment

​Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as UCSD and the Barrow Neurological Institution, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Learn more about Global Cancer Technology’s remote-controlled cancer drug delivery platform by clicking here.

COVID-19 Nanoparticle Treatment

​The coronavirus is mutating uncharacteristically fast. New strains are 50-70% more transmissible. The “UK Variant” [B.1.1.7] is now in 45 countries. Two other variants, the “South Africa Variant” [B.1.351] and one recently identified in Brazil could render existing treatments ineffective. Scott Gottlieb, the former director of the FDA, stated: “The South Africa variant is very concerning right now because it does appear that it may obviate some of our medical countermeasures, particularly the antibody drugs.

GCT has developed a method that targets coronavirus with high specificity and binds irreversibly to the virus particles. Once bound, an ultra-low dose x-ray (about 400 times less than a typical chest x-ray) activates the nanoparticles bound to the virus. Activation causes a blast of ultra-violet to be emitted directly into the coronavirus which kills it with timed precision.

Learn more about Global Cancer Technology's COVID-19 nanoparticle treatment by clicking here.

Glioblastoma Treatment

If you’re one of the 10,000 people in the USA diagnosed or a family member of one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. Nearly all patients diagnosed die within 12-18 months.

Some cancers, including brain cancer, have been historically underfunded despite the grim prognosis for those patients diagnosed. No doubt this is a direct corollary to why some cancers, like glioblastoma, have relatively few to no treatment options.

Research shows that 80% of the instances of recurrence, which are inevitable, appear in the tissue surrounding the resection cavity. The blood-brain barrier imposes biological limitations that make it easier for cancerous cells to invade the brain than it is for them to exit the brain and metastasize elsewhere. That sounds almost encouraging until you begin to discuss drug delivery: most therapeutics have high molecular weights beyond the range suitable for drug transport. Check point inhibitors which modulate biological pathways are generally effective in the treatment of most diseases: not so for glioblastoma.

Targeted delivery using nanoparticles to transport highly selective inhibitors across the blood-brain barrier remains the next frontier for treatment. “Glioblastoma requires an arsenal to combat,” said Dr. TBD, “we view the combination of improved targeting with localized delivery of specific inhibitors designed to penetrate the blood-brain barrier, potentially with radioactivated nanoparticles, as a novel modality worthy of further exploration.” GCT has recently acquired two patents for medicinal compounds that are known to cross the blood-brain barrier: PI3K and Vps34 act in mechanistically distinct manners as potent inhibitors of pathways commonly associated with cancers

Dr. Ekokobe Fonkem

Dr. Ekokobe Fonkem, director of neuro-oncology and an associate professor and chair in the Department of Neurology at Barrow Neurological Institute.

It takes a team effort

In collaboration with world renowned researchers and institutions, including the Barrow Neurological Institute, the University of San Diego and more, we are developing innovative treatments to fight deadly diseases like cancer, COVID, and other diseases.

“Incurable diseases like glioblastoma, commonly called ‘brain cancer,’ impose a high degree of suffering in patients who have few to no options regarding treatment. Being part of a collaborative effort around the creative application of new technologies gives us hope for a better future for these patients.”

Need more info before becoming an investor?

​GCT’s RegA+ presents investors with an unusual offer.
Following the close of a previous investment round at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment that looks promising for multiple forms of cancer, including cancers that are difficult to access and treat like brain cancer.

Management

The Company also has a non-compensated Medical Advisory Board. Some members of the Company’s Medical Advisory Board are shareholders in American Radiosurgery, Inc. The Medical Advisory Board is not expected to have day-to-day operational responsibilities for the Company. Additional biography information on the Medical Advisory Board members is provided herein.

John P. Clark

CEO

Mr. Clark brings over 35 years of medical sales and business experience and is the founder, Chairman and CEO of Global Cancer Technology, Inc. Mr. Clark specializes in the development and commercialization of medical technologies into going corporate concerns. Mr. Clark has purchased technologies and develop patents for various medical applications. Concurrently, Mr. Clark serves as a Board of Director and Chairman of the Board Finance Committee for Palomar Health, a $1.5 Billion asset California District Hospital System. Most recently Mr. Clark has founded and organized:

American Radiosurgery, Inc. The Company produced and sold the RGS Vertex360, a multi-million dollar radiosurgery device that competed with the Elekta Gamma Knife in treating brain tumors noninvasively with precise radiation. It was the first American Company to produce a competitive device to the Gamma Knife and systems were placed in the US and in International markets.

The Rotating Gamma Institute–Orange County and the Rotating Gamma Institute–San Diego. These companies are independent non-invasive brain tumor treatment centers that began as partnerships with neurosurgeons, radiation oncologists and other private investors.

Marc Potvin

President

Marc has 25 years in operations, sales & marketing, engineering, supply chain and strategy roles throughout the US and globally. He has spent the past 15 years’ experience in the medical device market space.

Marc is a seasoned entrepreneur who founded Agility Management in 2008, a Human Capital company sold in 2015. He has served as a Board member of Connect/SDSI, a leading business incubator for start-ups that is based in San Diego. Marc will serve as President of NanoMed Tracking, Inc, a subsidiary of Global Cancer Technology, Inc. Marc has been instrumental in the development of the medical instrument marking process within NanoMed Tracking, Inc.

Mr. Peter Hanson

Chief Financial Officer

Mr. Hanson has over 30 years of experience in the areas of finance and operations. He began his career in public accounting and became a partner with Arthur Young & Company, the predecessor of Ernst & Young.

As an audit partner, Mr. Hanson handled a wide variety of clients, both public and privately held. His responsibilities included being the head of the Emerging Business practice for the Boston Office of Arthur Young. After leaving Arthur Young, Mr. Hanson has experienced a wide variety of experiences including serving as Chief Financial Officer for NuCorp Energy and Mitchell International. He also was a principal of Polaris Capital, an investment-banking firm that specialized in leveraged buy-outs.

In addition to financial responsibilities, Mr. Hanson also has considerable operations experience as he also served as Executive Vice President of Operations for Mitchell International and more recently as President of the American Association of Franchisees and Dealer.

Milan Makale. PhD, MSEE

Chief Technical Officer

Dr. Makale has been a scientist at UCSD since 2001. He is a Research Scientist-Bioengineer in Neuro-Oncology at the Moores Cancer Center. Dr. Makale has a PhD in radiation biology and MSEE (electrical engineering and computer science) specializing in biomedical engineering with a focus on development of radiation sensitizers, cell cycle checkpoint inhibitors, theranostic nanoparticles, neurotechnology and neural devices.

Board of Directors

The Board of Directors of the Company is primarily responsible for and charged with overseeing all business and operations of the Company. The Board elects the president as well as all other officers of the Company who in turn are primarily responsible for the day-to-day business and operations of the Company.

John P. Clark

Mr. Clark has served as CEO of the Company since its inception in 2017 and served as manager of the Company’s predecessor, Global Cancer Technology LLC since 2013. He has also served as CEO of NanoMed Tracking, Inc., the Company’s subsidiary, since its inception in 2017. He has served as Chairman and CEO of American Radiosurgery, Inc. since 2001. Mr. Clark received a Bachelor of Science degree in biology in 1974 from the University of Scranton, Pennsylvania.

Mr. Tom Silberg

Thomas H Silberg is a seasoned professional in the Pharmaceutical and Biopharmaceutical Industries with substantial executive level experience, including major branded pharmaceuticals, medium sized biotech, start-up biotech and generic IV drug manufacturing. He has led multiple strategic transactions from a company divestiture and a public company spin out to asset acquisitions and partnerships. His career began in 1972 with Hoffmann La Roche, Inc. where he started in sales and advanced to VP of Business Operations.

He is a graduate from the University of Minnesota, where he earned a BS degree in Advertising and Marketing His past Board appointments include the USC Center of Excellence in HealthCare Management, Medi Promotions, the Cobalis Corporation and the Generic Pharmaceutical Manufacturers Association. He is currently a member of the Board of Directors for Pivotal Biosciences, Cardiocell, LLC, and Stemcutis, LLC and serves as Chairman of the Board for Genway Biotech, Inc., and the Palomar Health System Foundation.

Mr. Peter Hanson

Mr. Hanson has over 30 years of experience in the areas of finance and operations. He began his career in public accounting and became a partner with Arthur Young & Company, the predecessor of Ernst & Young. As an audit partner, Mr. Hanson handled a wide variety of clients, both public and privately held. His responsibilities included being the head of the Emerging Business practice for the Boston Office of Arthur Young. After leaving Arthur Young, Mr. Hanson has experienced a wide variety of experiences including serving as Chief Financial Officer for NuCorp Energy and Mitchell International.

He also was a principal of Polaris Capital, an investment-banking firm that specialized in leveraged buy-outs. In addition to financial responsibilities, Mr. Hanson also has considerable operations experience as he also served as Executive Vice President of Operations for Mitchell International and more recently as President of the American Association of Franchisees and Dealers.

Scientific & Medical Advisory Group

Central to Global Cancer Technology, Inc.’s strategic direction is the identification and development of proprietary products and platform technologies to better meet identified clinical demand. The Scientific Advisory Group plays a key role in meeting this objective. The charter for this Group is to work with the Global Cancer Technology, INC. and the Manufacturing Division to identify and advise on new proprietary devices and consider technologies with broad clinical applications.

Dr. Santosh Kesari

Dr. Santosh Kesari is a world-renowned board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute. He is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal.

He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech start-ups.

Dr. Kesari graduated from University of Pennsylvania, School of Arts and Sciences in 1992 and earned a Ph.D. degree in molecular biology and a M.D. from the University of Pennsylvania, School of Medicine. He completed his residency in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School and his neuro-oncology fellowship at the Dana-Farber Cancer Institute in Boston.

He was previously assistant professor of neurology at Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women’s Hospital and then professor of neurosciences at UC San Diego.

Sadik Esener, PhD

Applied Physics and Electrical Engineering from UCSD Professor of Nanoengineering and Electrical and Computer Engineering at UC San Diego. Internationally known expert in photonics, opto-electronics, and cancer nanotechnology. Sadik served as director of major research centers including NCI funded NanoTumor Center at UCSD. Specializes in cancer nanotechnology, in vivo imaging, optical systems and their interface with electronics and software. Sadik has been closely involved with 12 startup companies as co-founder including Genoptix, Nanogen, OriMedix, Devacell, and Ziva. Authored more than 350 publications.

Wolf Wrasidlo, PhD

Organic Chemistry from San Diego State University & University of Erlangen. Highly experienced polymer and organic chemist. Head of the Chemical Biology Program at the Moore’s Cancer Center at the UC San Diego School of Medicine and a Research Scientist in the Department of Neuroscience. Held senior level positions at The Scripps Research Institute, Humboldt University Berlin Medical School, University of Tuebingen Childrens' Hospital, and Columbia University. Distinguished Research Fellow at TargeGen, a Founder and the Head of Research at Brunswick Biotechnetics, a Research Scientist at General Atomics, and a member of the Member- Macromolecular Chemistry Group at the Boeing Scientific Research Institute and founder of Neuropore. Milan Makale, PhD, Radiation Biology at the University of Alberta.

Dr. Ted Dubinsky

Dr. Ted Dubinsky serves as the Lawrence A. Mack Endowed Professor of Radiology, Obstetrics and Gynecology, University of Washington School of Medicine and as the Editor in Chief of Ultrasound Quarterly. Dr. Dubinsky is a well-published and highly recognized luminary in the field of High Intensity Focused Ultrasound, having authored over 100 published peer review papers. At the University of Washington, Dr. Dubinsky served as the Director of Body Imaging an Adjunct Associate Professor of Obstetrics and Gynecology. Dr. Dubinsky achieved his medical degree from the University of Maryland after graduating from Johns Hopkins University.

Dr. Aizik Wolf

Dr. Wolf is a world-renowned radiosurgery neurosurgeon who has performed more private practice brain cancer treatments with gamma knife radiosurgery than any other neurosurgeon in the world. A member of numerous professional organizations, including the American Medical Association, American Association of Neurological surgeons, and the International Brain Research Organization, Dr. Wolf is also a founding member of the International Radiosurgery Support Association.

Dr. Wolf has been the recipient of numerous grants and research awards. He has acted as principal investigator for two clinical trials involving treatment for severe head injury, both of which were funded by the National Institutes of Health. Also, the American College of Surgeons presented Dr. Wolf and his investigative team with a Research Award for an abstract detailing a lobectomy procedure. Widely published, Dr. Wolf has authored and co-authored numerous book chapters and journal articles on neurological surgery, including work published in Advances in Neurology and the Journal of Neurosurgery.

He has presented his research as an honoured speaker and invited lecturer at many medical meeting and conferences around the world, such as the Annual Meeting of the American Association of Neurological Surgeons, the Society for Neuroscience and the International Stereotactic Radiosurgery Society.

Dr. Wolf graduated summa cum laude from Yale Medical School and trained at the University of Minnesota Hospitals. Earlier in his career, Dr. Wolf served as chief of epilepsy and skull-base surgery at the University of Maryland and assistant professor of neurology and neurosurgery. He received his Gamma Knife training at Brown University.

Dr. Wolf founded the Miami Neuroscience Center in 1993. Over the past two decades, he and his team have performed nearly 7,000 Gamma Knife surgeries, acquiring a level of expertise unmatched in the field. The team's long-time collaboration also led to a number of medical breakthroughs. The team was the first to make extensive use of radiosurgery to manage multiple metastases. It was also one of the first to apply radiosurgery to treat large-sized benign tumors, and the first nationally to provide Gamma Knife treatments on an outpatient basis.

Professor Dr. László Bognár

Professor Bognar graduated from Semmelweis University in 1982 and then obtained a specialist qualification in neurology and neurosurgery in 1986 and 1989, respectively. As of 2005, he has been director of the Clinic of Neurosurgery at the Centre of Medical and Health Sciences of Debrecen University, associate professor, as of 2006, professor. Apart from leading the Clinic, he is an external consultant in child neurosurgery at the Institute.

His key area of specialization is the research and treatment of brain tumors. He is greatly experienced in the surgical treatment of cerebrospinal fluid (CSF) circulation disorders, in epileptic surgery and in the operative treatment of cranial deformities. Professor Bognar founded the Rotating Gamma Institute-Debrecen and placed the first Rotating Gamma System (RGS) in Eastern Europe. Professor Bognar lectures around the world on stereotactic radiosurgery.

Dr. Maheep Gaur

In 1996 he joined fellowship program in Stereotactic Functional Neurosurgery and Radiosurgery at Stereotaxis and Gamma Knife centre, Fujieda Heisei Memorial Hospital, Shizuoka, Japan, under Dr. Tatsuo Hirai and Dr. Takaaki Takizawa, During this fellowship he participated in about 500 Gamma Knife Surgeries and Micro-recording assisted functional neurosurgery procedures for movement disorders. He learnt various aspects of stereotactic frame based and frameless neuro navigation.

On return to India in 1997 he joined Vidyasagar Institute of Mental Health and Neuro Sciences [Vimhans] at New Delhi India as Consultant Neurosurgeon. In 1998 he established first Gamma Knife centre in a dedicated neuroscience centre in SAARC region. He was designated head of Gamma knife Surgery at Vimhans. He has experience of more than 2000 Gamma Knife Treatments collectively. He is the founder of the Asian Radiosurgery Conference and conducted first Asian Gamma Knife Training Program at Saitama Japan.

Updates

May 30
Proactive Investors - an Interview with John Clark, Founder of GCT

Global Cancer Technology (GCT) CEO and founder, John Clark, was recently interviewed by Proactive Investors Online regarding GCT's atypically fast SEC approval for a Reg A+ shares filing. The $9 million fundraising round ongoing now is focused on applying a novel drug delivery treatment and brain cancer inhibitor to advance efforts in managing glioblastoma. Glioblastoma, also known as "brain cancer," is notoriously challenging to treat and the majority of those diagnosed die 18-20 months later. For patients and their loved ones, this is a heart-breaking diagnosis.

In his Proactive Investors interview, John also highlighted that, a portion of GCT's net proceeds will be used to develop and commercialize its recently licensed technology to treat the coronavirus using nanoparticles, UV light and chest x-rays. See the rest of the interview at the links below.

 

Additional Coverage can be found here:

May 23
One GCT Anti-cancer Inhibitor Looks Promising - NEW RESULTS

Let's begin with the disclaimer that biotechnology is an undpredicatable industry. When you're dealing with biological systems, even meticulously planned research can yield surprises in the results; and those surprises can be welcome or they can be devestating. Investing in biotechnology is a high-risk - you may lose your investment. That said, we've made some exciting progress with our pre-clinical research and have some results to share.

Experimental anti-cancer inhibitors are often highly toxic - they have to be to block the destructive growth ability of cancer cells. However, they are often so toxic that they not only halt cancer cell growth, but they kill the cancer cells - and neighboring healthy cells.

These are early studies but our May 2021 results show that the experimental inhibitor currently being investigated by GCT shows significantly reduced cellular growth by 48h - without kills the cells. The results enable GCT to move forward to the next set of experiments now that an "effective dose" has been identified which halts cancer cell growth but doesn't kill the cancer cells (or neighboring cells).

Below, human glioblastoma cells (cultured in a lab test-tube) - the inhibitor on the left is not as effective at halting cancel cell growth as the inhibitor tested on the right.

 

More background reading below...

Global Cancer Technology’s platform is what’s referred to as a Novel Drug-Delivery System, or “NDDS.” This refers to new approaches, technologies, and systems for transporting medicine into the body. Unlike conventional systems, NDDS combine advanced techniques with superior dosing regimens. According to Kenneth Research, a market research company, the global market for NDDS is projected to reach $320 billion by 2021.

Global Cancer Technology’s system is designed to target one of the world’s leading causes of death: cancer. In 2019, 1.7 million Americans were diagnosed with cancer. More than 600,000 of them will die from it. According to the American Cancer Society, men and women have around a 40% chance of developing cancer in their lifetime. Current treatment options aren’t effective, and can cause harmful side effects.

Chemotherapy, for example, attempts to eliminate cancer cells throughout a patient’s entire body. But chemo drugs can’t tell the difference between cancerous cells and healthy cells. As a result, it kills them both. This creates debilitating side effects.

Global Cancer Technology’s drug delivery platform reduces these side effects by ensuring that cancer treatments target only the tumor. Here’s how:

The company has created a nanoparticle that attaches to a cancer-fighting drug. More specifically, cancer drug molecules are linked to Scintillating NanoCrystals, which act as the delivery vehicle and can travel throughout the body easily. This linking process is part of the patented technology Global Cancer Technology has licensed.

Because they’re linked, the cancer drug molecules are “inactive.” When the nanoparticle reaches the tumor, the Scintillating NanoCrystals are exposed to a low dose of radiation. They then “light up,” breaking the links that bind them to the cancer drug.

As a result, the previously inactive drug molecules are activated at the site of the tumor. And because the level of radiation is so low, the damage sustained to the body is significantly less compared to traditional high-dose regimens.

Global Cancer Technology has gathered pre-clinical data on its platform, and engaged in advanced conversations with companies that have proven track records in drug-delivery development. These include NantHealth (Nasdaq: NH), a company developing and marketing healthcare solutions.

NantHealth’s investors include Celgene, a biotech company with $15 billion in annual revenues, and Allscripts Healthcare Solutions (Nasdaq: MDRX).

Moving forward, Global Cancer Technology aims to complete feasibility and pre-clinical tests, followed by a six-month clinical study of its platform. This will include a Phase I human trial and tests for safety and side effects.

Once on the market, Global Cancer Technology’s platform could be leveraged by leading pharmaceutical companies, such as Novartis (NYSE: NVS), Johnson & Johnson (NYSE: JNJ), Sanofi (Nasdaq: SNY), or Eli Lilly (NYSE: LLY).

Team Background

John Clark - CEO

John Clark has more than 25 years of experience in the medical industry.

He was Founder and CEO of American Radiosurgery, a San Diego-based company providing surgeons with neurosurgical equipment. This was the first company in the U.S. to create a device for the use of rotating gamma technology, a surgical technique that enables doctors to more precisely treat brain tumors.

Prior to that, he was a financial partner at Endolase, a medical company focused on creating surgical lasers used in cataract surgery procedures.

John studied at the University of Scranton.

Dr. Santosh Kesari - Advisor

Dr. Kesari is among the top 1% of neuro-oncologists in the U.S., according to Castle Connolly Medical, a healthcare research company.

He is Chairman of the Department of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute, and is Director of NeuroOncology at Providence Saint John’s Health Center.

Dr. Kesari is on the advisory board of the American Brain Tumor Association, San Diego Brain Tumor Foundation, and the Nicolas Conor Institute.

He earned a Ph.D. in Molecular Biology and an M.D. from the University of Pennsylvania School of Medicine.

Sadik Esener - Advisor

Sadik specializes in cancer nanotechnology, in-vivo imaging, and optical systems.

He is a professor of Nanoengineering and Electrical and Computer Engineering at UC, San Diego, and was Director of major research centers including the NCI-funded NanoTumor Center at UCSD.

He holds degrees in Applied Physics and Electrical Engineering.

Wolf Wrasidlo - Advisor

Wolf is Head of the Chemical Biology program at the Moores Cancer Center at UC San Diego. He’s held senior level positions at The Scripps Research Institute and Columbia University.

He earned an Organic Chemistry degree from San Diego State University.

Milan Makale - Advisor

Milan is a faculty member at UC San Diego’s Moores Cancer Center, where he specializes in medical devices and imaging.

He is a member of the American Chemical Society and earned a degree in Radiation Biology from the University of Alberta.

Dr. Aizik Wolf - Advisor

Dr. Wolf is a radiosurgery neurosurgeon.

He’s a member of the American Medical Association and the American Association of Neurological Surgeons.

He was an associate professor at the University of Maryland and graduated summa cum laude from Yale Medical School.

Comments

Post comment

Joseph Washington on May 07
this is a great biotech company to invest in they have great potential in fighting the war on cancer and especially covid-19 that's why I'm an shareholder and investor and a true believer that this company will succeed in its goal to cure and stop all types of cancers and viruses and deceases in America and abroad

John on May 31
Joseph - thank you for your support and for taking the time to make this post. Everyone at GCT is committed to finding new treatments for deadly diseases.

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/26358

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.